38 results
Thumbnail

D1.306 - Cold-induced urticaria: Phenotypic characterization and risk factors for cold-induced anaphylaxis

Thumbnail

D1.307 - Lipid metabolic remodeling in Food-induced anaphylaxis revealed by integrated proteomic and lipidomic analyses

Thumbnail

D1.313 - Clinical Characteristics of Chronic Urticaria Patients With and Without Flares With Systemic Symptoms

Thumbnail

D1.315 - IgE antibody function and mast cell activation to egg in children undergoing baked and loosely cooked egg challenges

Thumbnail

D1.319 - Efficacy of Omalizumab in Refractory Cholinergic Urticaria and Cholinergic Anaphylaxis: A Case Series

Thumbnail

D1.304 - Exercise-induced anaphylaxis misdiagnosed as cholinergic urticaria in a child: a case report

Thumbnail

D1.308 - Severe Chronic Spontaneous Urticaria with Recurrent Anaphylaxis and Extreme IgE Elevation Associated with Innate Immune Dysregulation

Thumbnail

D1.309 - The complexity of basal serum tryptase levels: Genotyping tryptase genes is not enough

Thumbnail

D1.314 - Endothelial glycocalyx shedding in IgE- and IgG-mediated anaphylaxis

Thumbnail

D1.316 - Identification of lipid classes to differentiate anaphylactic from non-anaphylactic allergic reactions. BANA study

Thumbnail

D1.317 - Systemic inflammatory indices in relation to anaphylaxis symptoms in adults with food allergy

Thumbnail

D1.320 - IgE-mediated Perioperative Anaphylaxis to Latex with Concomitant Local Anesthetic Hypersensitivity in a Mexican Teenager: a Policy-Changing Case Report

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to